Fig. 3.
Fig. 3. OS of Bcl-2–immunopositive DLCL patients with Bax-low and Bax-intermediate/high tumors. OS, comparing Bcl-2–immunopositive patients (n = 28) whose tumors contained low percentages (≤10%) of Bax-immunostained malignant cells (n = 9) with those that contained higher percentages (<10%) of Bax-immunopositive patients (n = 19; P < .01).

OS of Bcl-2–immunopositive DLCL patients with Bax-low and Bax-intermediate/high tumors. OS, comparing Bcl-2–immunopositive patients (n = 28) whose tumors contained low percentages (≤10%) of Bax-immunostained malignant cells (n = 9) with those that contained higher percentages (<10%) of Bax-immunopositive patients (n = 19; P < .01).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal